1. Home
  2. BOLT vs NCPL Comparison

BOLT vs NCPL Comparison

Compare BOLT & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLT
  • NCPL
  • Stock Information
  • Founded
  • BOLT 2015
  • NCPL 1984
  • Country
  • BOLT United States
  • NCPL United States
  • Employees
  • BOLT N/A
  • NCPL N/A
  • Industry
  • BOLT Biotechnology: Pharmaceutical Preparations
  • NCPL Investment Managers
  • Sector
  • BOLT Health Care
  • NCPL Finance
  • Exchange
  • BOLT Nasdaq
  • NCPL Nasdaq
  • Market Cap
  • BOLT 16.8M
  • NCPL 19.3M
  • IPO Year
  • BOLT 2021
  • NCPL N/A
  • Fundamental
  • Price
  • BOLT $5.65
  • NCPL $4.79
  • Analyst Decision
  • BOLT Buy
  • NCPL
  • Analyst Count
  • BOLT 3
  • NCPL 0
  • Target Price
  • BOLT $50.00
  • NCPL N/A
  • AVG Volume (30 Days)
  • BOLT 20.2K
  • NCPL 950.3K
  • Earning Date
  • BOLT 08-12-2025
  • NCPL 07-28-2025
  • Dividend Yield
  • BOLT N/A
  • NCPL N/A
  • EPS Growth
  • BOLT N/A
  • NCPL N/A
  • EPS
  • BOLT N/A
  • NCPL N/A
  • Revenue
  • BOLT $3,638,000.00
  • NCPL $812,612.00
  • Revenue This Year
  • BOLT N/A
  • NCPL N/A
  • Revenue Next Year
  • BOLT $24.14
  • NCPL $101.16
  • P/E Ratio
  • BOLT N/A
  • NCPL N/A
  • Revenue Growth
  • BOLT N/A
  • NCPL N/A
  • 52 Week Low
  • BOLT $5.20
  • NCPL $1.41
  • 52 Week High
  • BOLT $15.60
  • NCPL $11.90
  • Technical
  • Relative Strength Index (RSI)
  • BOLT 47.50
  • NCPL 46.57
  • Support Level
  • BOLT $5.68
  • NCPL $4.04
  • Resistance Level
  • BOLT $6.40
  • NCPL $7.40
  • Average True Range (ATR)
  • BOLT 0.27
  • NCPL 1.32
  • MACD
  • BOLT 0.07
  • NCPL -0.27
  • Stochastic Oscillator
  • BOLT 50.00
  • NCPL 14.95

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

Share on Social Networks: